Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Primacor
Milrinone is a phosphodiesterase-3 inhibitor that increases the force and velocity of cardiac contraction and produces systemic and pulmonary vasodilation. It is classified as an inotropic agent and is used in the short-term management of acute decompensated heart failure. It works by increasing intracellular calcium levels in cardiac myocytes, leading to increased contractility. Milrinone also inhibits phosphodiesterase-3 in vascular smooth muscle, resulting in vasodilation and decreased preload and afterload.
For short-term management of acute decompensated heart failure.
Outcome:
Increased risk of hypotension
Mechanism:
Additive hypotensive effects
Outcome:
Increased risk of hypotension
Mechanism:
Additive hypotensive effects
Outcome:
May reduce milrinone absorption
Mechanism:
Chelation
Most likely new formulation: Extended release formulation (Year: 2026, 60% confidence)
Based on historical usage patterns and current clinical trials, there is a low ( <5%) likelihood of a major regulatory change in the next 2 years.
Inotropic Agent, Vasodilator
Bipyridine